Cargando…
In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model
Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858384/ https://www.ncbi.nlm.nih.gov/pubmed/36673046 http://dx.doi.org/10.3390/diagnostics13020236 |
_version_ | 1784874085603344384 |
---|---|
author | Csikos, Csaba Vágner, Adrienn Nagy, Gábor Kálmán-Szabó, Ibolya Szabó, Judit P. Ngo, Minh Toan Szoboszlai, Zoltán Szikra, Dezső Krasznai, Zoárd Tibor Trencsényi, György Garai, Ildikó |
author_facet | Csikos, Csaba Vágner, Adrienn Nagy, Gábor Kálmán-Szabó, Ibolya Szabó, Judit P. Ngo, Minh Toan Szoboszlai, Zoltán Szikra, Dezső Krasznai, Zoárd Tibor Trencsényi, György Garai, Ildikó |
author_sort | Csikos, Csaba |
collection | PubMed |
description | Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission tomography using radiolabeled target-specific antibodies (immuno-PET) provides the longitudinal and quantitative assessment of tumor target expression. Due to antibodies having a long-circulating time, radioactive metal ions (e.g., (52)Mn) with longer half-lives are the best candidates for isotope conjugation. The aim of our preclinical study was to assess the biodistribution and tumor-targeting potential of (52)Mn-labeled DOTAGA-bevacizumab. The VEGF-A targeting potential of the new immuno-PET ligand was assessed by using the VEGF-A expressing KB-3-1 (human cervix carcinoma) tumor-bearing CB17 SCID mouse model and in vivo PET/MRI imaging. Due to the high and specific accumulation found in the subcutaneously located experimental cervix carcinoma tumors, [(52)Mn]Mn-DOTAGA-bevacizumab is a promising PET probe for the detection of VEGF-A positive gynecological tumors, for patient selection, and monitoring the efficacy of therapies targeting angiogenesis. |
format | Online Article Text |
id | pubmed-9858384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98583842023-01-21 In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model Csikos, Csaba Vágner, Adrienn Nagy, Gábor Kálmán-Szabó, Ibolya Szabó, Judit P. Ngo, Minh Toan Szoboszlai, Zoltán Szikra, Dezső Krasznai, Zoárd Tibor Trencsényi, György Garai, Ildikó Diagnostics (Basel) Article Among humanized monoclonal antibodies, bevacizumab specifically binds to vascular endothelial growth factor A (VEGF-A). VEGF-A is an overexpressed biomarker in cervix carcinoma and is involved in the development and maintenance of tumor-associated neo-angiogenesis. The non-invasive positron emission tomography using radiolabeled target-specific antibodies (immuno-PET) provides the longitudinal and quantitative assessment of tumor target expression. Due to antibodies having a long-circulating time, radioactive metal ions (e.g., (52)Mn) with longer half-lives are the best candidates for isotope conjugation. The aim of our preclinical study was to assess the biodistribution and tumor-targeting potential of (52)Mn-labeled DOTAGA-bevacizumab. The VEGF-A targeting potential of the new immuno-PET ligand was assessed by using the VEGF-A expressing KB-3-1 (human cervix carcinoma) tumor-bearing CB17 SCID mouse model and in vivo PET/MRI imaging. Due to the high and specific accumulation found in the subcutaneously located experimental cervix carcinoma tumors, [(52)Mn]Mn-DOTAGA-bevacizumab is a promising PET probe for the detection of VEGF-A positive gynecological tumors, for patient selection, and monitoring the efficacy of therapies targeting angiogenesis. MDPI 2023-01-08 /pmc/articles/PMC9858384/ /pubmed/36673046 http://dx.doi.org/10.3390/diagnostics13020236 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Csikos, Csaba Vágner, Adrienn Nagy, Gábor Kálmán-Szabó, Ibolya Szabó, Judit P. Ngo, Minh Toan Szoboszlai, Zoltán Szikra, Dezső Krasznai, Zoárd Tibor Trencsényi, György Garai, Ildikó In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model |
title | In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model |
title_full | In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model |
title_fullStr | In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model |
title_full_unstemmed | In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model |
title_short | In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [(52)Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model |
title_sort | in vivo preclinical assessment of the vegf targeting potential of the newly synthesized [(52)mn]mn-dotaga-bevacizumab using experimental cervix carcinoma mouse model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858384/ https://www.ncbi.nlm.nih.gov/pubmed/36673046 http://dx.doi.org/10.3390/diagnostics13020236 |
work_keys_str_mv | AT csikoscsaba invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT vagneradrienn invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT nagygabor invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT kalmanszaboibolya invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT szabojuditp invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT ngominhtoan invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT szoboszlaizoltan invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT szikradezso invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT krasznaizoardtibor invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT trencsenyigyorgy invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel AT garaiildiko invivopreclinicalassessmentofthevegftargetingpotentialofthenewlysynthesized52mnmndotagabevacizumabusingexperimentalcervixcarcinomamousemodel |